MedPath

Black Diamond Therapeutics

Black Diamond Therapeutics logo
🇺🇸United States
Ownership
Public
Established
2017-01-01
Employees
54
Market Cap
-
Website
http://www.blackdiamondtherapeutics.com
Introduction

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Clinical Trials

7

Active:5
Completed:0

Trial Phases

2 Phases

Phase 1:6
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (85.7%)
Phase 2
1 (14.3%)

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1
Active, not recruiting
Conditions
Non-Small Cell Lung Cancer
Metastatic Lung Non-Small Cell Carcinoma
EGFR-TKI Resistant Mutation
Advanced Non-Small Cell Squamous Lung Cancer
Metastatic Lung Cancer
NSCLC
Advanced Lung Carcinoma
Epidermal Growth Factor Receptor C797S
Epidermal Growth Factor Receptor G719X
EGF-R Positive Non-Small Cell Lung Cancer
Interventions
Drug: silevertinib (BDTX-1535) monotherapy
Drug: BDTX-1535 monotherapy
First Posted Date
2022-02-25
Last Posted Date
2025-07-11
Lead Sponsor
Black Diamond Therapeutics, Inc.
Target Recruit Count
200
Registration Number
NCT05256290
Locations
🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

City of Hope Comprehensive Cancer Center (Duarte Campus), Duarte, California, United States

and more 38 locations

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Phase 1
Terminated
Conditions
Solid Tumor
Interventions
First Posted Date
2019-12-24
Last Posted Date
2025-04-17
Lead Sponsor
Black Diamond Therapeutics, Inc.
Target Recruit Count
91
Registration Number
NCT04209465
Locations
🇺🇸

9250, Scottsdale, Arizona, United States

🇺🇸

9405, Long Beach, California, United States

🇺🇸

9474, Orange, California, United States

and more 35 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.